Table of ContentsView AllTable of ContentsGlioblastoma RecurrenceSurgery (Reoperation)Tumor Treating FieldsImmunotherapyComplementary Alternative TherapiesLife Expectancy/PrognosisCoping
Table of ContentsView All
View All
Table of Contents
Glioblastoma Recurrence
Surgery (Reoperation)
Tumor Treating Fields
Immunotherapy
Complementary Alternative Therapies
Life Expectancy/Prognosis
Coping
Glioblastoma recurrence is, unfortunately, the rule rather than the exception. Even when it appears a tumor has been eliminated with treatment, there is a high chance it will return. Sadly, there have also been relatively few treatment options when these cancers come back. Several newer treatments have been approved or are in clinical trials, but since these are so new, it can be hard to navigate the information to even find early results.
We will take a look at the statistics on glioblastoma recurrence and why the disease is so challenging to treat relative to many other cancers. We will also explore some of the potential treatment options including immunotherapy, tumor treating fields, angiogenesis inhibitors, and the latest information looking at how diet (such as the ketogenic diet) may play a role in treatment as well.
Due to the complexity of glioblastoma, treatment has been most effective using a combination of modalities, and it’s important to understand the rationale of some of these so that you can personally weigh the potential benefits and risks to you as an individual.
Chinnapong/iStock/Getty Images
Unfortunately, even when glioblastoma is discovered and treated aggressively, it almost always recurs. It is this very high recurrence rate that is the reason there are so few long term survivors of the disease.
Statistics
Without treatment, overall survival may only be a few months. With the treatment of surgery, radiation, and chemotherapy, the average overall survival is 14 to 16 months with some modest fluctuation based on factors like age, extent of tumor removed, mutations that the tumor does/does not have, and baseline function. The five-year survival is 5%.
Even when the tumor appears to have been eliminated, the median time to recurrence (the time where the cancer has come back for half of the people and has still not appeared for the other half) is 9.5 months.
For children, the numbers are slightly more optimistic, with a five-year survival rate for pediatric glioblastoma of 17%.
These numbers reinforce the need to look carefully at new therapies for both initial and recurrent glioblastoma, especially in light of recent advances in the treatments of some other cancers.
Challenges in Treating Glioblastoma
As we hear of advances in the treatment of other aggressive cancers such as metastatic melanoma or lung cancer, it’s easy to wonder why similar progress hasn’t been seen with glioblastoma. To understand this, as well as the challenges when evaluating treatment, it’s helpful to look at how glioblastoma differs from some other cancers with regard to both the initial treatment and treatment after recurrence.
Treatment Options
That said, many of these newer treatments have only recently been evaluated in humans, and it’s too soon to know what the potential long-term benefit may be. Without offering false hope, it is important that, while very uncommon, some of these treatments (such as tumor treating fields and a few immunotherapy options), have been associated with long-term survival for at least a few people.
Repeating surgery for glioblastoma has been linked to better overall survival as well as survival after progression of glioblastoma, but it’s thought that this benefit may be overestimated.
For people with recurrent glioblastoma who receive a checkpoint inhibitor (a type of immunotherapy) prior to surgery, the combination was linked to significantly improved survival in a 2019 study. In this small study of only 35 patients, people were treated with the immunotherapy drug Keytruda (pembrolizumab) prior to surgery. Those who received both Keytruda and surgery lived much longer (overall survival of 13.7 months) compared with those who only had surgery (7.5 months).
The combination of Keytruda and surgery almost doubled survival relative to surgery alone.
While this may not seem to be a large amount of time, it is very significant with a tumor that has been so challenging to treat and is so rapidly fatal without treatment. In the future, adding additional therapies (such as an oncolytic virus or other treatment) to these treatments will likely be considered.
Tumor treating fields (Optune) were approved for treating recurrent glioblastoma in 2011 (and have more recently been approved for newly diagnosed glioblastoma as well). The treatment uses low-intensity, intermediate-frequency, alternating electric fields to interfere with cell division in cancer cells.
The treatment, fortunately, has very little effect on normal, healthy brain cells. Optune was initially approved because it has fewer side effects than other treatments that offered similar improvements in survival. Since that time, Optune has been found to have a benefit on survival as well.
In a clinical trial, people with recurrent glioblastoma were either given tumor treating fields or the physician’s choice of chemotherapy. There was no statistically significant difference in survival of the two groups but the tumor treating field group reported a greater quality of life and fewer side effects.
With Optune, small transducers are applied to the scalp and attached to a battery pack. While the device must be worn most of the time (at least 18 hours each day) to be effective, it is usually well-tolerated. Tumor treating fields may be used for tumors in the upper part of the brain (supratentorial) but not for tumors in the back of the brain (the cerebellum).
In some cases (roughly 15% of people), the tumor may appear to initially worsen before responding to tumor treating fields, and this has been seen even in people who have had a “durable response” (were alive seven years after the treatment was started).
Tumor Treating Fields as a Cancer Treatment
Immunotherapyis a type of treatment that uses the immune system, or principles of the immune system, to treat cancer. There are, however, many different types of immunotherapy with a few options offering hope in treating recurrent glioblastoma.
Checkpoint Inhibition
As noted above under surgery, combining one type of immunotherapy (a checkpoint inhibitor) before surgery has a significant benefit on survival rate with recurrent glioblastoma. However, the kind of responses sometimes seen with melanoma and lung cancer to these drugs have yet to be seen with glioblastoma. It’s thought that part of the reason is that glioblastomas have fewer of a type of immune cells known as T cells in the tumor.
That said, the possibility of combining checkpoint inhibitors with other treatments (for example, oncolytic virus therapy or IL-12) offers hope.
Oncolytic Viruses
One of the more optimistic therapies being studied for recurrent glioblastoma is that of oncolytic viruses. There are several viruses that have been considered and/or evaluated in the lab or in clinical trials on humans, and while some effectiveness has been seen, larger clinical trials are needed. Some of these include DNX-2401 (a recombinant adenovirus), a polio-rhinovirus chimera, parvovirus H-1, Toca 511, dentritic cell vaccines, and more.
DNX-2401 (tasadenoturev):A clinical trial using a different oncolytic adenovirus (DNX-2401) in people with recurrent glioblastoma also offered promising results, though the study was primarily done to test safety. In this study, 20% of the people treated were alive after three years, and 12% had a reduction of 95% or more of their tumor.
Other Immunotherapy Options
Several other types of immunotherapy have either been studied to some degree or may be evaluated in the near future. One example is CAR T cell therapy, a treatment that uses a person’s ownT cells(that are collected and modified) to fight cancer.
While only recently studied in humans, immunotherapy options such as oncolytic viruses offer hope.
Radiation
Re-treating with radiation may sometimes be helpful in improving both survival and quality of life with recurrent glioblastoma.Stereotactic body radiotherapy(SBRT or Cyberknife) is a type of high-dose radiation delivered to a small area of tissue and may offer benefit with less radiation exposure.
Chemotherapy
Chemotherapymay be used for recurrent glioblastoma. When chemotherapy has been previously used, either different drugs or higher doses of the previous drugs are often used. The drug TMZ (temozolomide) is used in the initial treatment of glioblastoma, and occasionally at recurrence. Cytoxan (cyclophosphamide) and CCNU/CuuNu/Gleostine (lomustine) are other options.
Angiogenesis Inhibitors
In order for tumors to grow, they need to recruit new blood vessels to supply the tumor with nutrients; a process calledangiogenesis. Angiogenesis inhibitors (such as Avastin) have been used along with chemotherapy with some benefit.
Avastin (bevacizumab) was approved in December of 2017 for recurrent glioblastoma, and unlike the severe side effects (such as bleeding) seen in using it to treat some other types of cancer, it seems to have fewer side effects with glioblastoma. Thus far, while it does appear to improve progression-free survival, an effect on overall survival has not yet been seen. That said, for people who received the drug after a first or second recurrence roughly 8% of people were classified as achieving “long term survival.”
Endostatin (recombinant human endostatin) is a very strong angiogenesis inhibitor. It can be used with cytotoxic drugs to treat recurrent disseminated glioblastoma.
Other Targeted Therapies
While the exception, some glioblastomas contain targetable mutations that may be addressed with currently available drugs, and when properly identified and treated, may have a large impact on survival, at least short term. DNA sequencing (DNA and RNA) can identify these anomalies.
DNA sequencing (DNA and RNA) of a glioblastoma tumor may identify people who could benefit from targeted therapies.
Other Treatments
A number of other therapies are also being evaluated in clinical trials including boron neutron therapy, the targeted therapy anlotinib, the STAT3 inhibitor WP1066, Toca 511, exportin inhibitors, and more.
When faced with a cancer that has few treatment options, many people wonder about the option of complementary/alternative therapies. In talking about research in this area, it’s important to note that these alternative therapies arenotused as a substitute for conventional medical care, but rather as an adjunct to help symptoms and possibly improve the effectiveness of conventional treatments.
In fact, a 2018 study found that people who refused standard care to use alternative remedies were more than twice as likely to die from their disease.
Fortunately, recent research looking specifically at glioblastoma suggests that some of these options may play a role in treatment (but only with the very careful guidance of a physician) when combined with standard care.
Intermittent Fasting and the Ketogenic Diet
Intermittent fasting takes many forms, but the type usually considered with cancer is prolonged nighttime fasting, or limiting the consumption of food to a period of roughly eight hours each day. The theory behindintermittent fasting and canceris that healthy cells adapt much better to changes (such as a decrease in calories) than cancer cells. In laboratory and animal studies, fasting appeared to increase the response of glioma cells to radiation and chemotherapy.
The ketogenic diet, or “ketogenic metabolic therapy” (KMT) likewise has been found to have effects on glioblastoma cells in the lab and animal studies significant enough to have some researchers asking whether ketogenic metabolic therapy should become standard of care for glioblastoma. The diet both reduces the amount of glucose available in the brain (to “feed” the cancer) and produces ketone bodies that seem to have a protective effect on the brain.
Since laboratory and animal studies don’t necessarily translate into effects on humans, it’s important to look at the few human trials to date. The purpose of these early studies is primarily to address safety and tolerability issues (feasability studies).
In a small 2019 in adults with glioblastoma, there were no adverse effects among those who used the ketogenic diet in combination with chemotherapy and radiation. A different 2019 study looked at the use of the ketogenic diet in children with recurrent pontine glioblastoma. It found that side effects were only mild and transient.
The Ketogenic Diet and Cancer: Potential Risks and Benefits
Cannabinoids
A discussion of the potential treatment options for recurrent glioblastoma would not be complete without mentioning cannabinoids. It is the studies on glioblastoma cells in the lab and animals, in fact, that have given rise to some of the public opinion that “weed might fight cancer.”
Both laboratory and animal studies have demonstrated cannabinoids to have some effectiveness in treating glioma, and this is consistent with the possible mechanisms of action. While human research is lacking, a phase II study does suggest that cannabinoids may have a positive role on survival, and should be studied more thoroughly in the future.
For those who are using cannabis (under the guidance of their oncologist) for other reasons such as to improve appetite or help with nausea, this research may be reassuring.
It’s difficult to talk about “average” life expectancy for recurrent glioblastoma for many reasons, but one good reason is that new treatments are being studied, and it’s still too early to know if these will change the prognosis.
There are several factors that affect prognosis, including:
Even with these factors, however, it’s important to realize that every person and every tumor is different. Some people do very well despite having a very poor prognosis, and vice versa.
Coping with a tumor that has the statistics of glioblastoma can be incredibly lonely. Cancer is a lonely disease to begin with, but with glioblastoma, even talking to survivors of other types of cancer may leave you feeling isolated.
Support is Essential
Some people have found immense support via support groups. Since glioblastoma is less common than some other cancers, and the treatments so different, many people with the disease prefer an online support community composed of others coping specifically with glioblastoma. Not only are these groups a source of support, but they can be educational.
It’s now become relatively common for people to learn about new therapies and clinical trials through their connections with other survivors. After all, it is often people living with the disease who are most motivated to learn about the latest research.
Clinical Trials With Recurrent Glioblastoma
With glioblastoma, it’s also important for people to understand the purpose, potential risks, and potential benefits ofclinical trials. Many of the newer treatments that are being used for glioblastoma are only being used in clinical trials at the current time.
While the term clinical trial can be frightening, these studies have changed significantly in the recent past. Whilephase I trialsin the past were mostly studies that could benefitotherpeople in the future (and had almost no chance of helping the person in the study), these earliest of human trials can now sometimes make a difference in the survival of the person participating.
In some cases this has been dramatic. In other cases (as seen originally with tumor treating fields in recurrent glioblastoma), a treatment may not obviously improve survival more than other treatments, but may have much fewer side effects.
The reason for this isprecision medicine. Instead of randomly studying a compound to see what might happen in people who have cancer, most of the treatments being evaluated today have been carefully designed in pre-clinical studies to target specific pathways in the growth of cancer.
Second Opinions
Getting a second opinion, preferably at one of the larger National Cancer Institute designated cancer centers is something to consider. A 2020 study found that people with glioblastoma who were treated at centers that saw larger volumes of patients with glioblastoma had better outcomes.
Difficult Discussions and Decisions
Talking about the chance that nothing will help is difficult, but these conversations are very important for people with cancer and their families alike. What are your wishes? The language surrounding cancer has done a disservice to many people living with the disease. Cancer isn’t a fight that either you or the cancer wins; even when a cancer progresses you are still a winner. You win with how you live your life while you are here.
Courage does not mean receiving treatments that drastically reduce your quality of life with little potential benefit. Sometimes it takes the greatest courage to forego some of these efforts. Most importantly, your cancer is your journey, not that of someone else. In whatever choices you make, whether regarding treatment or how to spend these days, make sure you honor your own heart.
What to do When You are Diagnosed with Terminal Cancer
A Word From Verywell
If you have or are worried that you have experienced a recurrence of glioblastoma, you are probably feeling more than frightened. Looking at statistics alone can leave you with a sense that there are few choices. Without tossing out false hope or minimizing your fears, we mention some of the studies above (though we know it can be totally overwhelming) so that you can see that researchisin progress. Not only research in a dish in the lab or in mice, but early results of clinical trials in humans looking at immunotherapy, tumor treating fields, and other options that are showing promise. That said, and for now, it’s likely that the “ideal” treatment will remain a combination of therapies rather than any single drug or treatment.
22 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Fabian D, guillermo Prieto Eibll MDP, Alnahhas I, et al.Treatment of glioblastoma (GBM) with the addition of tumor-treating Fields (TTF): A review.Cancers. 2019;11(2).pii:E174. doi:10.3390/cancers11020174
Delgado-Lopez PD, Corrales-Garcia EM.Survival in glioblastoma: A review on the impact of treatment modalities.Clinical Translational Oncology.2016. 18(11):1062-1071. doi:10.1007/s12094-016-1497-x
Liu M, Thakkar JP, Garcia CR, et al.National cancer database analysis of outcomes in pediatric glioblastoma.Cancer Medicine.2018;7(4):1151-1159. doi:10.1002/cam4.1404
Stensjoen AL, Solheim O, Kvistad KA, et al.Growth dynamics of untreated glioblastomas in vivo.Neuro-oncology.2015;17(10):1402-11. doi:10.1093/neuonc/nov029
Zhao YH, Wang ZF, Pan ZY, et al.A meta-analysis of survival outcomes following reoperation in recurrent glioblastoma: Time to consider the timing of reoperation.Frontiers in Neurology.2019;10:286. doi:10.3389/fneur.2019.00286
Cloughesy TF, Mochizuki AY, Orpilla JR, et al.Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.Nature Medicine.2019;25(3):477-486. doi:10.1038/s41591-018-0337-7
Burri SH, Gondi V, Brown PD, Mehta PM.The evolving role of tumor treating fields in managing glioblastoma: Guide for oncologists.American Journal of Clinical Oncology.2018;41(2):191–196. doi:10.1097/COC.0000000000000395
Vymazal J, Wong ET.Response patterns of recurrent glioblastomas treated with tumor-treating fields.Seminars in Oncology.2014;41(Suppl 6):S14-24. doi:10.1053/j.seminoncol.2014.09.009
Desjardins A, Gromeier M, Herndon JE, et al.Recurrent glioblastoma treated with recombinant poliovirus.New England Journal of Medicine.2018;379(2):150-161. doi:10.1056/NEJMoa1716435
Lang FF, Conrad C, Gomez-Manzano C, et al.Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: Replication and immunotherapeutic effects in recurrent malignant glioma. Journal of Clinical Oncology.2018;36(14):1419-1427. doi:10.1200/JCO.2017.75.8219
Nassiri F, Patil V, Yefet LS, et al.Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.Nat Med. 2023;29(6):1370-1378. doi:10.1038/s41591-023-02347-y
Kim IH.Appraisal of re-irradiation for the recurrent glioblastoma in the era of MGMT promotor methylation.Radiation Oncology Journal.2019;37(1):1-12. doi:10.3857/roj.2019.00171
Morisse MC, Etienne-Selloum N, Bello-Roufai D, et al.Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: A multicentric retrospective study.Journal of Neurooncology.2019;144(2):419-426. doi:10.1007/s11060-019-03245-5
Ge JJ, Li C, Qi SP, Xue FJ, Gao ZM, Yu CJ, Zhang JP.Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study.BMC Cancer. 2020;20(1):24. doi:10.1186/s12885-019-6467-6
Zhang X, Zhang T, Davis JN, et al.Mucin-like domain of Ebola virus glycoprotein enhances selective oncolytic actions against brain tumors. Journal of Virology.2020. doi:10.1128/JVI.01967-19
Johnson SB, Park HS, Gross CP, Yu JB.Use of alternative medicine for cancer and its impact on survival.Journal of the National Cancer Institute.2018;110(1). doi:10.1093/jnci/djx145
Safdie F, Brandhorst S, Wei M, et al.Fasting enhances the response of glioma to chemo- and radiotherapy.PLoS One.2012;7(9):e44603. doi:10.1371/journal.pone.0044603
Seyfried TN, Shelton L, Arismendi-Morillo G, et al.Provocative question: Should ketogenic metabolic therapy become the standard of care for glioblastoma?Neurochemical Research.2019;44(10):2392-2404. doi:10.1007/s11064-019-02795-4
van der Louw EJTM, Olieman JF, van den Bemt PMLA, et al.Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: A feasibility and safety study.Therapeutic Advances in Medical Oncology.2019;11:1758835919853958. doi:10.1177/1758835919853958
van der Louw EJTM, Reddingius RE, Olieman JF, et al.Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study.Pediatric Blood Cancer.2019;66(3):e27561. doi:10.1002/pbc.27561
Dumitru CA, Sandalcioglu IE, Karsak M.Cannabinoids in glioblastoma therapy: New applications for old drugs.Frontiers in Molecular Neuroscience.2018;11:159. doi:10.3389/fnmol.2018.00159
Chen Z, Xu N, Zhao C, et al.Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials.Cancer Management Research. 2018;10:2193-2205. doi:10.2147/CMAR.S173323Ge JJ, Li C, Qi SP, et al.Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study.BMC Cancer. 2020;20(1):24. doi:10.1186/s12885-019-6467-6Iv M, Liu X, Lavezo J, et al.Perfusion MRI-based fractional tumor burden differentiates between tumor and treatment effect in recurrent glioblastomas and informs clinical decision-making.AJNR American Journal of Neuroradiology.2019;40(10):1649-1657. doi:10.3174/ajnr.A6211Lv Y, Zhang J, Liu F, et al.Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review.Medicine (Baltimore). 2019;98(22):e15749. doi:10.1097/MD.0000000000015749National Cancer Institute.Cannabis and cannabinoids (PDQ)-health professional version. Updated 01/07/2020.O’Rourke DM, Nasrallah MP, Desai A, et al.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Science Translational Medicine.2017;9(399). pii: eaaa0984. doi:10.1126/scitranslmed.aaa0984Schafer N, Gielen GH, Rauschenbach L, et al.Longitudinal heterogeneity in glioblastoma: Moving targets in recurrent versus primary tumors.Journal of Translational Medicine. 2019;17(1):96. doi:10.1186/s12967-019-1846-ySkaga E, Kulesskiy E, Brynjulvsen M, et al.Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment.Clinical Translational Medicine. 2019;8(1):33. doi:10.1186/s40169-019-0253-6Stepanenko AA, Chekhonin VP.Recent advances in oncolytic virotherapy and immunotherapy for glioblastoma: A glimmer of hope in the search for an effective therapy?Cancers.2018;10(12). pii: E492. doi:10.3390/cancers10120492Wick W, Gorlia T, Bendszus M, et al.Lomustine and bevacizumab in progressive glioblastoma.New England Journal of Medicine.2017;377(20):1954-1963. doi:10.1056/NEJMoa1707358Woolf EC, Curley KL, Liu Q, et al.The ketogenic diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model.PLoS One. 2015. 10(6): e0130357. doi:10.1371/journal.pone.0130357
Chen Z, Xu N, Zhao C, et al.Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials.Cancer Management Research. 2018;10:2193-2205. doi:10.2147/CMAR.S173323
Ge JJ, Li C, Qi SP, et al.Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study.BMC Cancer. 2020;20(1):24. doi:10.1186/s12885-019-6467-6
Iv M, Liu X, Lavezo J, et al.Perfusion MRI-based fractional tumor burden differentiates between tumor and treatment effect in recurrent glioblastomas and informs clinical decision-making.AJNR American Journal of Neuroradiology.2019;40(10):1649-1657. doi:10.3174/ajnr.A6211
Lv Y, Zhang J, Liu F, et al.Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review.Medicine (Baltimore). 2019;98(22):e15749. doi:10.1097/MD.0000000000015749
National Cancer Institute.Cannabis and cannabinoids (PDQ)-health professional version. Updated 01/07/2020.
O’Rourke DM, Nasrallah MP, Desai A, et al.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Science Translational Medicine.2017;9(399). pii: eaaa0984. doi:10.1126/scitranslmed.aaa0984
Schafer N, Gielen GH, Rauschenbach L, et al.Longitudinal heterogeneity in glioblastoma: Moving targets in recurrent versus primary tumors.Journal of Translational Medicine. 2019;17(1):96. doi:10.1186/s12967-019-1846-y
Skaga E, Kulesskiy E, Brynjulvsen M, et al.Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment.Clinical Translational Medicine. 2019;8(1):33. doi:10.1186/s40169-019-0253-6
Stepanenko AA, Chekhonin VP.Recent advances in oncolytic virotherapy and immunotherapy for glioblastoma: A glimmer of hope in the search for an effective therapy?Cancers.2018;10(12). pii: E492. doi:10.3390/cancers10120492
Wick W, Gorlia T, Bendszus M, et al.Lomustine and bevacizumab in progressive glioblastoma.New England Journal of Medicine.2017;377(20):1954-1963. doi:10.1056/NEJMoa1707358
Woolf EC, Curley KL, Liu Q, et al.The ketogenic diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model.PLoS One. 2015. 10(6): e0130357. doi:10.1371/journal.pone.0130357
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
